Major Scientific Research Projects

• 2020

  Jun.

  The "AKT inhibitor intermediates" project obtained the Shanghai High-tech Achievement Transformation Project Certificate.

  Jul.

  The "Entresto intermediates" project obtained the Shanghai High-tech Achievement Transformation Project Certificate.

  Aug.

  Identified as a Shanghai Patent Work Demonstration Enterprise.

  Sept.

  The "Cobimetinib intermediates" project and the "BET protein inhibitor intermediates" project obtained the Shanghai High-tech Achievement Transformation Project Certificate.

  Nov.

  Chemexpress has been approved by the “Shanghai Science and Technology Small Giant” project.

  Dec.

  The "Ivacaftor intermediates" project obtained the Shanghai High-tech Achievement Transformation Project Certificate.

  Dec.

  Recognized as a Pudong New Area Corporate R&D Institution.
• 2019

  Apr.

  In April, the "Tacarbitol" project obtained the Shanghai High-tech Achievement Transformation Project Certificate.

  Dec.

  In December, the "Trabectedin (raw material)" project obtained the Shanghai High-tech Achievement Transformation Project Certificate.
• 2018

  Dec.

  In December, the "Alcalcidol Intermediate" project was approved for the "High-tech Achievement Transformation Project".
• 2017

  Dec.

  In December, the "Highly Active Anti-tumor New Drug R&D Platform" was successfully approved for the special fund project of "Small and Micro Enterprise Entrepreneurship Innovation Base City Demonstration".
• 2016

  Aug.

  In August, the " research and development of MMAE series of antibody-coupled drug" project was successfully approved for the 2016 Shanghai Innovation Fund.
• 2015

  Jul.

  In July,the " research and development of a new drug for hepatitis C treatment of sofosbuvir and its tablets" was successfully approved for the Shanghai "Science and Technology Innovation Action Plan" for the cooperation project of industry-university-research-medicine in the biomedical field.

  Aug.

  In August, the " Preparation Platform of Polypeptide Drugs" Project was successfully established in 2015 Pudong Science and Technology Development Fund

  Sept.

  In September, the "industrialization of carfilzomib and its advanced intermediates and research and development of new anti-tumor drugs" projectwas successfully approved forthe Shanghai "Science and Technology Innovation Action Plan" technology innovation fund project fortechnology-based small and medium-sized enterprises.
• 2014

  Jun.

  In June, the "Teliliptin and its key intermediates research and development" project was successfully approved for the 2014 Shanghai Innovation Fund.
• 2013

  Jun.

  In June, the characteristic vitamin D series product "Research and Development of Paricalcitol and Its Intermediates" was successfully approved for the 2013 Shanghai Innovation Fund.
• 2011

  Oct.

  In October, the "Innovative Research and Development of Asenapine Synthetic Process" project was successfully approved for the 2011 Shanghai Innovation Fund.
• 2009

  Sept.

  In September, "chiral fully synthetic natural product triptolide and novel anti-tumor activity triptolide derivatives" project was successfully approved for the 2009 Shanghai Innovation Fund.
• 2007

  May.

  In May, Chemexpress and Fudan University jointly undertook the National 863 Program "Discovery and Evaluation of New Anti-TB Lead Compounds". Chemexpress was awarded the excellent supplier of Schering-Plough's new drug customization service.